Additionally, the project will assess the medical and nonmedical costs of MRSA infections and quantify the potential savings attributable to different preventative treatments.
"MRSA containment and eradication is a national priority because of its virulence and rapid expansion in healthcare settings," Huang said. "This trial will provide a critically needed comprehensive evaluation of strategies to decrease MRSA infection risk across the continuum of inpatient and outpatient care."
Through its Health Policy Research Institute, UCI has become a nationwide leader in comparative effectiveness research, which explores the best possible treatment options for patients, based on criteria like age, gender, race and health history.
In 2009, the center's co-executive director, Dr. Sheldon Greenfield, helped chair an influential Institute of Medicine panel charged with advising the government on how to spend money allocated by Congress for comparative effectiveness research. It crafted a list of 100 healthcare priorities such as heart disease, Alzheimer's and cancer that became the foundation of the CHOICE program and related initiatives.
Greenfield also is co-investigator on two CHOICE-funded projects: A Vanderbilt University-led effort will identify the best use of radiation or surgery for various forms of prostate cancer. And one headed by UCLA will examine different approaches to congestive heart failure that limit the need for hospitalization.
"The commitment by the federal government to CHOICE and other comparative effectiveness programs will usher in new forms of research, leading to more effective personal care," said Greenfield, Donald Bren Professor of Medicine at UCI. "It ultimately will produce more tools for the physician and more options for the patient."
|Contact: Tom Vasich|
University of California -- Irvine